Solid Biosciences Inc. (SLDB)

NASDAQ: SLDB · IEX Real-Time Price · USD
0.467
-0.002 (-0.34%)
At close: Sep 30, 2022 4:00 PM
0.486
+0.019 (4.05%)
After-hours: Sep 30, 2022 7:55 PM EDT
-0.34%
Market Cap 52.72M
Revenue (ttm) 14.79M
Net Income (ttm) -87.01M
Shares Out 112.99M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,859,563
Open 0.501
Previous Close 0.468
Day's Range 0.467 - 0.575
52-Week Range 0.420 - 2.510
Beta 1.37
Analysts Buy
Price Target 5.51 (+1,080.9%)
Earnings Date Nov 1, 2022

About SLDB

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vecto... [Read more...]

Industry Biotechnology
IPO Date Jan 26, 2018
Employees 104
Stock Exchange NASDAQ
Ticker Symbol SLDB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for SLDB stock is "Buy." The 12-month stock price forecast is 5.51, which is an increase of 1,080.88% from the latest price.

Price Target
$5.51
(1,080.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Mer...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Bioscience...

1 day ago - Business Wire

SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Solid Biosciences Inc. (NASDAQ: SLDB) and AavantiBio, Inc. is fair to Solid shareholders....

2 days ago - Business Wire

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -

2 days ago - GlobeNewsWire

Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results

- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 -

1 month ago - GlobeNewsWire

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

4 months ago - GlobeNewsWire

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003. In additio...

5 months ago - Benzinga

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients ...

- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process -

5 months ago - GlobeNewsWire

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Inc (NASDAQ: SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD....

6 months ago - Benzinga

Solid Biosciences Inc. (SLDB) Reports Q4 Loss, Lags Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data fro...

- 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes compared ...

6 months ago - GlobeNewsWire

Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

7 months ago - GlobeNewsWire

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

8 months ago - GlobeNewsWire

All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy

Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 months ago - Zacks Investment Research

Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.79% and 7.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 -

10 months ago - GlobeNewsWire

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development -

11 months ago - GlobeNewsWire

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

11 months ago - GlobeNewsWire

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)-- #genetherapy--Solid and Forge Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

11 months ago - Business Wire

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

Other symbols: ECORPBTSUXINWIMI
1 year ago - InvestorPlace

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial...

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post admi...

1 year ago - GlobeNewsWire

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

Solid Biosciences Inc (NASDAQ: SLDB) reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001.  SGT-001 is a novel adeno-associated vir...

1 year ago - Benzinga

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital C...

1 year ago - GlobeNewsWire

Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research